The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen

Blood

Volumn 106, Issue 7, 2005, Pages 2329-2333

  Sconce, Elizabeth A ^b   Khan, Tayyaba I ^b   Wynne, Hilary A ^b   Avery, Peter ^b   Monkhouse, Louise ^b   King, Barry P ^b   Wood, Peter ^b   Kesteven, Patrick ^b   Daly, Ann K ^b   Kamali, Farhad ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; PROTEIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; AGED; ALLELE; ANTICOAGULATION; ARTICLE; BODY SIZE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CLEARANCE; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEIGHT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; WILD TYPE;

EID: 23044440450     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1108     Document Type: Article

References (28)

1. Hirsch J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J. Oral anticoagulants: mechanisms of action, clinical effectiveness and optimal therapeutic range. Chest. 1998;114:445S-469S.
2. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity aftermyocardial infarction. Lancet. 1994;343:499-503.
3. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
4. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med. 1993;118:511-520.
5. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
6. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
7. Kamali F, Khan TI, King BP, et al. Contribution of age, bodysize and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004;75:204-212
8. Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol. 1988;25:1-7.
9. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-541.
10. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105:645-649.
11. Bodin L, Verstuyft C, Tregouet D, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinant of acenocoumaraol sensitivity. Blood. 2005;106:135-140.
12. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719.
13. Beyth RJ, Quinn L, Landefeld CS. A multi-component intervention to prevent major bleeding complications in older patients receiving warfarin. Ann of Intern Med. 2000;133:687-695.
14. Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther. 2004;75:198-203.
15. Gedge J, Orme S, Hampton KK, Channer KS, Hendra TJ. A comparison of a low dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing. 2000;29:31-34.
16. Wilkinson T, Sainsbury R. Evaluation of a wafarin initiation protocol for older people. Intern Med J. 2003;33:465-467.
17. Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage. Lancet. 1998;352:1505-1509.
18. Fennerty A, Dolben J, Thomas P, et al. Flexible induction regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed). 1984;288:1268-1270.
19. Rowland M, Tozer, TN. Multiple dose regimens. In: Rowland M, Tozer TN, eds. Clinical Pharmacokenetics, Concepts and Implications. 3rd ed. Baltimore, MD: Williams & Wilkins; 1995:83-105.
20. King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004:14:813-827.
21. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod H. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91:87-94.
22. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96:1816-1819.
23. Wynne H, Cope L, Kelly P, Whittingham T, Edwards C, Kamali F. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Pharmacol. 1995;40:203-207.
24. Kamali F, Edwards C, Butler TJ, Wynne HA. The influence of R- and S-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation. Thromb Haemost. 2000;84:39-42.
25. Visser LE, Trienekens PH, De Smet PAGM, et al. Patients with an ApoE ε4 allele require lower doses of coumarin anticoagulants. Pharmacogenetics. 2005;15:69-74.
26. Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 2004;4:40-48.
27. Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX and X; protein S &C; and gamma glutamyl carboxylase) gene variants with warfarin sensitiviy. Blood. 2004;103:2630-2635.
28. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002;72:702-710.